Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casirivimab+Imdevimab in hospitalized pediatric COVID-19 patients
NCT05092581Phase 1Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of casirivimab + imdevimab in coronavirus disease 2019 (COVID-19), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Concentrations of casirivimab+imdevimab in serum over time at 169 days, Treatment-emergent serious adverse events at 29 days and 2 more. Started Dec 2021; status: terminated.
02
Drugs
casirivimab + imdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05092581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05092581.